Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial evaluating the efficacy and the biological activity of BAY 43-9006
in patients with recurrent and/or metastatic head and neck cancer.